EWTX Edgewise Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EWTX

Price (delayed)

$19.29

Market cap

$1.8B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.57

Enterprise value

$1.72B

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. ...

Highlights
Edgewise Therapeutics's debt has increased by 23% YoY but it has decreased by 2.1% from the previous quarter
The quick ratio has contracted by 11% YoY but it has grown by 7% from the previous quarter
The net income is down by 48% year-on-year and by 12% since the previous quarter
The EPS fell by 25% YoY and by 11% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://edgewisetx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of EWTX
Market
Shares outstanding
93.11M
Market cap
$1.8B
Enterprise value
$1.72B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.84
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$100.16M
EBITDA
-$98.43M
Free cash flow
-$97.69M
Per share
EPS
-$1.57
Free cash flow per share
-$1.53
Book value per share
$5.02
Revenue per share
$0
TBVPS
$5.34
Balance sheet
Total assets
$340.04M
Total liabilities
$21.21M
Debt
$5.41M
Equity
$318.83M
Working capital
$310.23M
Liquidity
Debt to equity
0.02
Current ratio
19.5
Quick ratio
18.98
Net debt/EBITDA
0.82
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-30.2%
Return on equity
-32.1%
Return on invested capital
-36.7%
Return on capital employed
-31%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EWTX stock price

How has the Edgewise Therapeutics stock price performed over time
Intraday
1.47%
1 week
21.02%
1 month
9.17%
1 year
120.46%
YTD
76.33%
QTD
5.76%

Financial performance

How have Edgewise Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$114.36M
Net income
-$100.16M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 60% year-on-year and by 11% since the previous quarter
The net income is down by 48% year-on-year and by 12% since the previous quarter

Growth

What is Edgewise Therapeutics's growth rate over time

Valuation

What is Edgewise Therapeutics stock price valuation
P/E
N/A
P/B
3.84
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 25% YoY and by 11% QoQ
The P/B is 140% more than the last 4 quarters average of 1.6
Edgewise Therapeutics's equity has increased by 10% from the previous quarter but it has decreased by 8% YoY

Efficiency

How efficient is Edgewise Therapeutics business performance
Edgewise Therapeutics's ROE has decreased by 44% YoY and by 15% from the previous quarter
EWTX's ROIC is down by 43% YoY and by 21% QoQ
EWTX's ROA is down by 42% year-on-year and by 14% since the previous quarter

Dividends

What is EWTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EWTX.

Financial health

How did Edgewise Therapeutics financials performed over time
The quick ratio has contracted by 11% YoY but it has grown by 7% from the previous quarter
EWTX's current ratio is down by 9% year-on-year but it is up by 7% since the previous quarter
Edgewise Therapeutics's debt is 98% less than its equity
Edgewise Therapeutics's debt to equity has surged by 100% YoY
Edgewise Therapeutics's debt has increased by 23% YoY but it has decreased by 2.1% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.